It has been reported that levels of viremia reflect the severity of illness in dengue virus infection. We assessed the levels of viremia in patients with primary and secondary infections, using 2 cell lines: FccR-expressing BHK cells and FccR-negative cells. In primary infection, virus titers were at similar levels between FccRexpressing and FccR-negative cells. In secondary infection, however, virus titers were 10 times higher in FccRexpressing cells on days 1-6 when compared with FccR-negative cells, indicating discrepancy in viremia titers between FccR-expressing and FccR-negative cells. The results suggest that dengue virus-antibody complexes with infectious capacity exist in patients with secondary infection, and these immune complexes can be detected by using FccR-expressing cells. As it has been reported that principal target cells of dengue virus infection are FccR-positive, monocyte/macrophage lineage cells, virus titers determined using FccR-expressing cells may better reflect the actual viremic conditions in vivo.
Dengue fever (DF)/ dengue hemorrhagic fever (DHF) is endemic in tropical and subtropical regions of the world. DF/ DHF is caused by infection with dengue virus (DENV), a group of 4 serotypes: DENV-1, DENV-2, DENV-3, and DENV-4. Infection with 1 serotype confers lifelong immunity to infection with homologous serotypes, but immunity to heterologous serotypes is short-lived. Primary DENV infection induces antibodies that are cross-reactive for heterologous DENV serotypes, as well as those specific for the infecting serotype. It has been reported that DHF occurs at higher rates in secondary infection with heterologous DENV serotypes than in primary infection. DENV cross-reactive antibodies, when present at subneutralizing concentrations, have been proposed to play a major role in the development of DHF by facilitating viral entry into FccR-expressing cells, which leads to higher viral progeny production [1, 2] . This immune enhancement may result in increase in total viremia levels leading to DHF.
High viremia titers are associated with increased disease severity [3] [4] [5] , and understanding of the detailed patterns of viremia is important for elucidating the pathogenesis of DF/DHF. The interpretation of viremia levels in the presence of antibodies, however, is complicated by several factors. Assessing virus levels by quantitative real-time PCR (RT-PCR) detects viral nucleic acids but not the infectious capability of virus particles. Interpretation of DENV viremia levels is further challenged by the ratio of flavivirus genomes to infectious particles, which could range from 1000:1 to 5000:1 [6] . Plaque titration methods that use FccR-negative cell lines such as Vero and BHK-21 cell lines [7] [8] [9] lack the capability of detecting infectious DENV-antibody immune complexes. As a result of exclusive detection of viral genomes using RT-PCR and virus titers using FccR-negative cells, the infectious capability of DENV-antibody immune complexes may not be accurately reflected.
DENV-antibody immune complexes are present in DHF and DSS patients [10] , and DENV in immune complexes has been detected by quantitative RT-PCR [11] . However, the ability of DENV-antibody immune complexes to infect FccR-expressing cells remains unclear. It is possible that DENV-antibody immune complexes have a different effect in FccR-positive cells and FccR-negative cells, leading to viremia levels that are different from those described in the literature. As the principal target cells of DENV are FccR-expressing cells such as monocyte/macrophage lineage cells, we reasoned that viremia titers determined using FccR-positive cells may better reflect viremia levels in vivo. In the present study, we determined whether the presence of DENV-antibody immune complexes leads to higher viremia titers in secondary infections, as determined using FccR-expressing cells.
MATERIALS AND METHODS

Serum Samples
Seventy-three serum samples from 54 dengue cases were used. The serum samples consisted of 42 serum samples obtained from 33 individuals with primary dengue virus infection and 31 serum samples from 21 individuals with secondary infection. These serum samples were obtained in clinics and hospitals in Japan, from the year 2004 to 2010, and sent to the National Institute of Infectious Diseases, Japan, for laboratory diagnosis of dengue. As all serum samples were deidentified, patient consent was not required. The study protocol has been approved by the institutional review board of the National Institute of Diseases, Japan. Demographics of the patient population sampled are summarized in Table 1 . Day after onset of disease is defined as the identification of first symptoms such as fever [12] .
Virologic and Serologic Studies
Virus serotypes were determined by a serotype-specific reverse transcriptase polymerase chain reaction (RT-PCR), and the virus RNA copy number was determined by quantitative fluorogenic RT-PCR [13] . The limit for detection for DENV-1 is #9.5 3 10 2 genome copies/mL; DENV-2, #4.7 3 10 2 genome copies/mL; DENV-3, #4.7 3 10 4 genome copies/mL and DENV-4, #6.5 3 10 4 genome copies/mL.
Dengue-virus specific immunoglobulin M (IgM) antibodies in serum samples were determined using IgM capture enzymelinked immunosorbent assay (ELISA) (Dengue Fever Virus IgM Capture ELISA, Focus Diagnostics) according to the manufacturer's instructions. Dengue indirect immunoglobulin G (IgG) ELISA (Panbio Ltd) was used for anti DENV-IgG antibodies according to the manufacturer's instructions. Primary infection (P) was defined by the absence of DENV-specific anti-DENV IgG antibodies at the stage of the absence or presence of anti-DENV IgM antibodies, and at the stage of virus isolation or viral RNA detection. Secondary infection (S) was defined by the presence of anti-DENV IgG antibodies at the stage of absence of anti-DENV IgM antibodies, and at the stage of virus isolation or viral RNA detection [14] . The definition of acute primary and secondary flavivirus infections was supported by DENV E/ M protein-specific IgM/ IgG OD ratios of $1.2 (primary infection) and ,1.2 (secondary infection) [15] . All the serum samples used were positive for DENV as detected by RT-PCR.
BHK-21 cells, a hamster kidney cell line, and, FccRIIA-expressing BHK-21 cells were used [16, 17] . BHK-21 cells were cultured in Eagles Minimum Essential Medium (EMEM, Sigma), supplemented with heat-inactivated 10% fetal calf serum (FCS) (Sigma), without antibiotics at 37°C in 5% CO 2 . FccRIIA expressing BHK-21 cells were cultured in EMEM (Sigma), supplemented with heat-inactivated 10% FCS (Sigma) and 0.5 mg/mL neomycin (G418, PAA Laboratories GmbH) at 37°C in 5% CO 2 .
Quantification of the Viremia Titer by Plaque Assay
Human serum samples were serially diluted 10-fold from 1:10 1 to 1:10 6 with EMEM supplemented with 10% FCS. Serially diluted serum samples were then incubated at 37°C for 1 h and used in infection experiments. Fifty microliters of diluted serum samples were inoculated onto BHK-21 monolayers in 12-well plates. The plates were incubated for 1 h at 37°C in 5% CO 2 . After virus absorption, the cells were overlaid with maintenance medium containing 1% methylcellulose (Wako Pure Chemical Industry). The plates were incubated at 37°C in 5% CO 2 until visible plaques could be observed (5 to 7 days of incubation). The cells were fixed with 3.7% (vol/vol) formaldehyde for 1 h at room temperature and washed with water. The cells were then stained with methylene blue solution for 1 h at room temperature and washed with water. Plaques were counted by naked eye. The viral titers were expressed as plaqueforming units per millimeter (PFU/mL), using the following formula: (number of plaques per well) 3 (dilution) / (inoculum volume). Twenty-five microliters of diluted serum samples were inoculated onto BHK-21 monolayers in 24-well plates. The plates were incubated for 1 h at 37°C in 5% CO 2 . After virus absorption, the cells were washed once with 0.5 mL EMEM and overlaid with 0.5 mL EMEM containing 10% FCS. The plates were incubated at 37°C in 5% CO 2 for 5 days. After 5 days of incubation, 200 lL of culture supernatant were collected and assayed by quantitative fluorogenic RT-PCR. Viral RNA was extracted from culture medium using a High Pure RNA extraction kit (Roche Diagnostics, Mannheim, Germany) and 5 ll of RNA solution was applied to TaqMan RT-PCR as previously described [13] .
Assessment of Contribution of Virus-Immune Complex to Viremia Titers
Heat-aggregated IgG was prepared by diluting whole IgG (Human IgG, Sigma) to 10 mg/mL in 0.9% saline and then heating at 65°C for 60 minutes [18] . One hundred micrograms of heat-aggregated IgG was then incubated onto each well of BHK-21 monolayers in 12-well plates. The cells were then incubated at 4°C for 20 minutes and washed once with EMEM. Serially diluted human serum samples were then applied to the cells and viremia titers were quantified by using plaque assay.
To react serum samples with (Fab') 2 anti-human IgG Fc antibody, ten micrograms of the antibody (goat anti-human IgG, Fc Fragment specific, Pierce) were added to each of the serially diluted human serum samples and incubated at 37°C for 1 h. Viremia titer was then quantified by plaque assay.
Statistics
Results were expressed as mean 6 SD The statistical significance of differences was determined by Students t test to compare the mean titers. The difference was considered to be significant when the P-value was ,.05. The fold increase in virus titer or V N /V O ratio was calculated by the formula: (Average virus titer assessed with FccR-expressing BHK cells, V N )/(Average virus titer assessed with FccR-negative BHK cells, V O ).
RESULTS
DENV Titers in Serum Samples From Dengue Patients With
Primary Infection Determined Using FcgR-Negative and FcgRIIA-Positive BHK Cells DENV titers in serum samples from dengue patients with primary infection were assessed, using FccR-negative BHK cells and FccRIIA-expressing BHK cells, by a conventional plaque titration method. Virus titers were at similar levels in both FccRIIA-negative BHK cells and FccRIIA-expressing BHK cells, for 14 of 15 anti-DENV IgM-negative, IgG-negative samples, and all the 10 anti-DENV IgM-positive, IgG-negative samples ( Table 2) . As an indicator of infection enhancement, the ratios of virus titers using FccR-expressing BHK cells (V N ) against those obtained using FccR-negative BHK cells (V O ) were calculated. The ratio ranged from 0.8 -1.5, suggesting no difference in titers except for P10a. No infectious virus was detected using either FccRIIA-expressing cells or FccR-negative cells in serum samples P6b, P17, P21, P22, P3b, P27, P29, and P30, and in 9 anti-DENV IgM-positive and IgG-positive serum samples tested (Table 2) .
DENV Titers in Serum Samples From Dengue Patients With Secondary Infection Determined Using FcgR-Negative and FcgRIIA-Positive BHK Cells
Similar assays were performed for serum samples from dengue patients with secondary infection. Twenty of 22 serum samples that had viremia levels above the detection limit of the plaque assay demonstrated higher viremia titers using FccRIIA-expressing BHK cells as compared with FccRIIAnegative BHK-21 cell lines (Table 3) . To assess the fold increase in virus titers, the V N /V O ratios were calculated as described in the Materials and Methods section. The V N /V O ratio of the 20 serum samples obtained from patients with secondary infection ranged from a 3.0-fold to as high as a 40-fold increase. Levels of viremia determined by using FccR-expressing cells were higher than those determined using FccR-negative cells, both in IgM-negative and IgG-positive samples, and IgM-positive and IgG-positive serum samples from patients with secondary infection. Two serum samples (S7 and S14), however, demonstrated similar levels of viremia both in FccR-expressing and FccR-negative cells. The virus titer of S16 was 4.85 log10 PFU/mL when assayed using FccR-expressing BHK cells, but it was below the detection limit when assayed with FccR-negative cells. The virus titer of serum sample S16 was 8.11 log10 genome equivalents/mL when determined by quantitative RT-PCR (Table 3 ). The results indicate that higher virus titers were detected using FccR-expressing BHK cells as compared with FccRnegative BHK cells, and this was observed in the presence or absence of anti-DENV IgM. Figure 1 ).
Time Course of Virus Titers
Virus titers were also determined in sequential serum samples from 4 patients with secondary DENV infection using FccR-expressing BHK cells and FccR-negative BHK cells.
Higher virus titers were detected on disease days 1-5 using FccR-expressing cells as compared with FccR-negative BHK cells (Figures 2A-2D) . The V N /V O ratios of these serum samples ranged from 3.0 to 40.0 (P , .05) between FccR-expressing BHK cells and FccR-negative BHK cells. 
Higher Viremia Titers in Patients With Secondary Infection Determined by FcgR-expressing Cells but not in Primary Infection
Average viremia titers were calculated from days 1-7 after onset of disease in 73 serum samples from 33 patients with primary infection ( Figure 3A ) and 21 patients with secondary infection ( Figure 3B ). Serum samples from primary infection did not exhibit higher virus titers when determined using FccR-expressing BHK cells as compared with FccR-negative BHK cells from disease days 1-5. Viremia was not detected for most of the samples tested on disease days 6 and 7. The rate of decrease in virus titers in patients with primary infection detected using FccR-negative BHK cells and FccR-expressing BHK cells (mean clearance rate, -0.92 vs -0.94 log10 PFU/ day) were similar to those with secondary infection using FccR-negative BHK cells and FccR-expressing BHK cells (mean clearance rate, -1.07 vs -1.10 log10 PFU/ day). There was no difference in the rates of decrease in virus titers using FccR-negative BHK cells in primary and secondary infection (primary infection vs secondary infection, P 5 .465), and when assayed with FccR-expressing BHK cells (primary infection vs secondary infection, P 5 .451). The estimated duration of detectable levels of viremia was longer using FccR-expressing cells in patients with secondary infection (mean duration detected using BHK cells vs FccR-expressing BHK cells, 6.9 days vs 7.4 days), but not in patients with primary infection (mean duration detected using BHK cells vs FccRexpressing BHK cells, 6.3 days vs 6.3 days). Using FccRexpressing BHK cells, the difference in virus titer was significant between primary and secondary infection on illness day 1 (P , .001), day 3 (P 5 .003), day 4 (P 5 .011), day 5 (P # .010), and, day 6 (P 5 .041). Using FccR-negative BHK cells, no significant difference in virus titer between primary and secondary infection was found on illness day 1 (P 5 .110), day 3 (P 5 .052), day 4 (P 5 .089), day 5 (P 5 .354), and day 6 (P 5 .087). Comparison of virus titer on illness day 2 was not performed due to insufficient number of secondary infection serum samples.
Reduction of Virus Titer in Serum Samples of Secondary Infection by Blockade of Immune Complex Binding to FcgR
To examine the contribution of infectious virus-antibody immune complex to viremia titers, FccR-expressing cells were 4 ) of serum samples from secondary infection (S4, S8, S9, and S15a) virus titer in culture supernatant fluids were consistently higher in FccR-expressing cells as compared with FccR-negative cells (P , .05). Virus titers were, however, not consistently higher in FccR-expressing cells than FccR-negative cells when primary infection serum samples were used. Thus, statistical analysis was performed using secondary infection serum samples. Results indicate geometric mean virus titer (genome copies/ mL) 6 SD of 2 replicates. Open bars indicate FccR-negative BHK cells, closed bars indicate FccR-expressing BHK cells, and (#) indicates virus titers below detection limits as in materials and methods.
exposed to heat-aggregated IgG antibodies prior to inoculation with viremic serum samples. Alternatively, human serum samples were allowed to react with F(ab') 2 anti-IgG Fc antibodies to block binding of the Fc-portion of IgG to FccR.
Two serum samples, S4 and S9, from patients with secondary infection were used. Higher virus titers were not detected using heat-aggregated (HA) IgG treated FccR-expressing cells and serum samples treated with anti-human IgG Fc fragment specific antibodies. Virus titers of serum sample S4 determined using FccR-BHK with HA-IgG 5 6.78 6 0.49 vs BHK 5 6.69 6 0.12 (P 5 .415), FccR-BHK with anti-IgG Fc antibody treated S4 5 6.87 6 0.04 vs BHK 5 6.69 6 0.12 (P 5 .077) (Table 4 ).
DISCUSSION
The extent to which the DENV-antibody immune-complex contributes to viremia titers has not been fully defined. In the present study, we demonstrated increased viremia titers and slower virus clearance using FccRIIA-expressing BHK cells in patients with secondary DENV infection. Higher viremia titers were detected using FccR-expressing BHK cells from 1 to 6 days after onset of disease in serum samples obtained from patients with secondary DENV infection as compared with viremia titers detected using FccR-negative BHK cells. There was no difference in the levels of viremia in serum samples from patients with primary DENV infection between FccR-expressing BHK cells and FccR-negative BHK cells. Constant detection of higher levels of viremia in secondary infection using FccR-expressing cells suggests the presence of DENV-antibody complexes that were infectious to FccR-expressing cells but not to FccR-negative cells. The observed higher levels of viremia in secondary infection suggest that infectious virus titers of 10 folds higher than those described in the literature exist in patients with secondary DENV infection.
It has been reported that higher viremia titers were detected in patients with secondary DENV-2 and dengue hemorrhagic fever (DHF), as compared with patients with dengue fever (DF) using RT-PCR [11] . Other investigators, however, reported no discrepancy in viremia between patients with secondary and primary infection [19, 20] , or, higher viremia in primary infection as compared with secondary infection [21] . In addition, due to the 2 competing antibody capacities against DENV (neutralization and enhancement), the antibodies may interfere in the interpretation of viremia levels [11] . However, other investigators reported that DENV were effectively recovered from patients with secondary infection vs FccR-BHK, 7.9 6 1.5 (P , .001), day 4; BHK, 5.3 6 1.5 vs FccR-BHK, 6.3 6 1.9 (P 5 .005). A similar tendency was detected on disease days 5 and 6, although the differences were not statistically significant: day 5; BHK, 4.5 6 1.6 vs FccR-BHK, 5.3 6 1.9 (P 5 .187), day 6; BHK, 2.6 6 0.6 vs FccR-BHK, 3.8 6 1.3 (P 5 .211). Virus titers were below detection limits using plaque titration methods for day 7; BHK , 2.3 vs FccR-BHK , 2.3.Open bars indicate FccRIIA-negative BHK cells, and closed bars indicate FccRIIA-expressing BHK cells. Results indicate geometric mean virus titer 6 SD.SD values were arithmetic SD derived from log10 transformed virus titers in PFU/mL. Error bars indicate 6 1 SD (#) indicates virus titer below detection limit using plaque titration (,2.30 log10 PFU/mL). P-value indicates comparison between virus titers determined by FccR-negative BHK cells and FccR-expressing BHK cells. ( ) indicates P $ .05, and, ( * ) indicates P ,.05.
using FccR-expressing mouse macrophages P388D1 cells as compared with FccR-negative C6/36 cells. The high rates of virus recovery using FccR-expressing cells suggest the presence of infectious DENV-immune complex in secondary infection [22] , which further supports our results.
One of the challenges encountered with textbook descriptions of dengue viremia levels is that the conventional titration method uses FccR-negative cells. Our results demonstrated that this classical description of viremia titers, however, holds true for primary infection in particular. In contrast, omission of the infectious capacity of the DENV-antibody complex in FccRexpressing cells has resulted in underestimated viremia levels during secondary infection, which consequently leads to a discrepancy in viremia titers of as much as one log PFU/mL (Table 3, Figure 3 ). The FccR-expressing BHK cells used in the present study consistently detected the sum of enhancing and neutralizing capacities of antibodies in the form of immune complexes [16, 17] . Blockade of antibody binding to FccR significantly reduced antibody-infection enhancement effect in FccR-expressing BHK cells: indicating that infectious virus-antibody complexes are present during DENV infection and contribute to the enhanced infection of FccR-expressing cells (Table 4) . Overall, these data suggest the presence of circulating DENVantibody immune complexes that are infectious to FccR expressing cells, but not to FccR-negative cells. Mammalian cells such as Vero, LLCMK, and BHK cells are commonly used in plaque assays as compared with C6/36 cells for virus titration [16, 23] . Virus titers in the cell culture supernatant fluids after DENV infection in the absence of antibodies in C6/36 cells were not higher than those of FccR-expressing BHK cells and FccRnegative BHK cells (author's unpublished data). As such, viremia titers detected using FccR-expressing BHK cells may better reflect in vivo conditions as the major DENV target cells expresses the FccR.
It has been speculated that the pathogenesis of severe DENV infection involves dengue serotype cross-reactive antibodies that enhance dengue infection resulting in higher viremia titers, one of the preludes for the development of severe dengue infection [24] . The observation of higher viremia titers using FccRIIAexpressing cells in patients with secondary infection as compared with primary infection may suggest that immune complex with infectious capacity only for FccR-expressing cells may, in part, contribute to severe dengue infection. These associations between higher viremia titers and the presence of infectious immune complexes during secondary dengue infection may be a key factor in understanding the pathogenesis of dengue infection.
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